Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Bevacizumab is an antibody that binds vascular endothelial growth factor and has activity in metastatic renal cell carcinoma (RCC). Interferon alfa (IFN-alpha) is the historic standard initial treatment for RCC. A prospective, randomized, phase III trial of bevacizumab plus IFN-alpha versus IFN-alpha monotherapy was conducted.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): J Clin Oncol

Title: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Publisher: American Society of Clinical Oncology (ASCO)

ISSN (Electronic): 1527-7755

ISSN (Print): 0732-183X

Publication date (Electronic): May 01 2010

Volume: 28

Issue: 13

Affiliations

[1 ] Department of Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Institute, 9500 Euclid Ave/Desk R35, Cleveland, OH 44195, USA. rinib2@ccf.org

Article

Publisher Item ID: JCO.2009.26.5561

DOI: 10.1200/JCO.2009.26.5561

PMC ID: 2860433

PubMed ID: 20368558

SO-VID: a723a1c5-facf-4726-9dd3-a80e9a2841cb

History

Data availability:

Comments

Comment on this article

scite_

Smart Citations

Citing PublicationsSupportingMentioningContrasting

View Citations

See how this article has been cited at scite.ai

scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.